Kanuma
Sebelipase alfa · SEBELIPASE ALFA 2 mg/mL · Injection, Solution, Concentrate · Intravenous · Alexion Pharmaceuticals, Inc.
NDC 25682-0007-01 · 1 VIAL, GLASS in 1 CARTON / 10 mL in 1 VIAL, GLASS · BLA · View full market →
Medicare Part D
No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.
How Part D pricing works →NADAC price per unit
No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.
Estimated fill cost
Manufacturer list price as filed — not what pharmacies actually pay after discounts.
Medicaid spend (2025)
Supply fragility
Not scored — fragility is computed for NADAC-priced NDCs.
Is this a "specialty" drug?
There's no legal definition — it meets 2 of 6 public criteria. Why that matters →
- Part D specialty tier
- Costs ≥ $950/fill
- Biologic (BLA)
- Injectable / infused
- Orphan-drug exclusivity
- REMS program
Regulatory
- Application
- BLA125561
- TE code
- —
- Approval date
- —
- Patents / exclusivity
- None on file
Shortage history
No FDA shortage reports for this drug or its presentations.
Recalls (this NDC)
No enforcement reports list this package NDC.
Manufacturers of Sebelipase alfa (Injection, Solution, Concentrate)
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| Alexion Pharmaceuticals, Inc. | SEBELIPASE ALFA 2 mg/mL | Jul 15, 2026 | Jul 29, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
Cite this page
DrugDashboards, "Kanuma — NDC 25682-0007-01," retrieved September 3, 2026, https://drugdashboards.com/drug/25682000701.
Free to cite with attribution — see how the data is put together.